Search Results - "Csepregi, A"

Refine Results
  1. 1

    Do Autoantibodies Predict Autoimmune Liver Disease in Primary Sjögren's Syndrome? Data of 180 Patients upon a 5 Year Follow‐Up by Csepregi, A., Szodoray, P., Zeher, M.

    Published in Scandinavian journal of immunology (01-12-2002)
    “…Objective: To evaluate the clinical value of autoantibodies as serological markers to predict autoimmune liver diseases in primary Sjögren's syndrome (SS)…”
    Get full text
    Journal Article
  2. 2

    Low prevalence of Helicobacteraceae in gall-stone disease and gall-bladder carcinoma in the German population by Bohr, U.R.M., Kuester, D., Meyer, F., Wex, T., Stillert, M., Csepregi, A., Lippert, H., Roessner, A., Malfertheiner, P.

    Published in Clinical microbiology and infection (01-05-2007)
    “…Colonisation of the hepatobiliary system with bile-resistant Helicobacter spp. has been proposed as a novel risk-factor in the pathogenesis of gall-bladder…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5

    Investigation of aerosol pollution inside trams in Debrecen, Hungary by Papp, E., Nagy, D., Szoboszlai, Z., Angyal, A., Török, Zs, Csepregi, Á., Furu, E., Kertész, Zs

    “…Fine (PMfine) and coarse (PMcoarse) particulate matter concentrations and elemental compositions were investigated inside trams during travelling in heating…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8
  9. 9

    C5b-9 and Interleukin-6 in Chronic Hepatitis C: Surrogate Markers Predicting Short-term Response to Interferon Alpha-2b by BIRO, L, VARGA, L, DALMI, L, ABONYI, M, FÜST, G, HORANYI, M, CSEPREGI, A, PAR, A, NEMESANSZKY, E, TELEGDY, L, IBRANYI, E, DAVID, K, HORVATH, G, SZENTGYÖRGYI, L, NAGY, I

    “…Background: Available data and our observations suggest that elevated levels of interleukin (IL)-6 and -10 and some complement parameters may be associated…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12
  13. 13

    Tolerability of sorafenib in the treatment of hepatocellular carcinoma (HCC) in patients with Child A and B liver cirrhosis by Schuette, K., Zimmermann, L., Bornschein, J., Huster, D., Csepregi, A., Malfertheiner, P.

    Published in Journal of clinical oncology (20-05-2009)
    “…Abstract only e15593 Background: Sorafenib (S) is the only drug that prolongs overall survival in patients (pts) with advanced HCC by nearly 3 months in pts…”
    Get full text
    Journal Article
  14. 14

    Eligibility of patients with hepatocellular carcinoma for systemic treatment with sorafenib by Zimmermann, L. C., Schuette, K., Borschein, J., Csepregi, A., Malfertheiner, P.

    Published in Journal of clinical oncology (20-05-2009)
    “…Abstract only e15673 Background: Sorafenib is the first systemic drug that effects prolonged overall survival in patients with advanced hepatocellular…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17
  18. 18

    The pathophysiology of portal hypertension by Treiber, Gerhard, Csepregi, Antal, Malfertheiner, Peter

    Published in Digestive diseases (Basel) (2005)
    “…Portal hypertension is defined by an elevation in blood pressure in the portal system. Different causes are known and include a pre-, intra-, or posthepatic…”
    Get more information
    Journal Article
  19. 19
  20. 20

    Do Autoantibodies Predict Autoimmune Liver Disease in Primary Sjoegren's Syndrome? Data of 180 Patients upon a 5 Year Follow-Up by Csepregi, A, Szodoray, P, Zeher, M

    Published in Scandinavian journal of immunology (01-12-2002)
    “…Objective: To evaluate the clinical value of autoantibodies as serological markers to predict autoimmune liver diseases in primary Sjoegren's syndrome (SS)…”
    Get full text
    Journal Article